home / stock / oyst / oyst news

OYST News and Press, Oyster Point Pharma Inc. From 02/18/21

Stock Information
Company Name: Oyster Point Pharma Inc.
Stock Symbol: OYST
Market: NASDAQ
Website: oysterpointrx.com
Menu
OYST OYST Quote OYST Short OYST News OYST Articles OYST Message Board
Get OYST Alerts

News, Short Squeeze, Breakout and More Instantly...
OYST - Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2020 Results - Earnings Call Transcript

Oyster Point Pharma, Inc. (OYST) Q4 2020 Earnings Conference Call February 18, 2021, 04:30 PM ET Company Participants Daniel Lochner - CFO Jeffrey Nau - President and CEO John Snisarenko - Chief Commercial Officer Conference Call Participants Anupam Rama - JPMorgan Tara Bancroft - Piper Sandl...
OYST - Oyster Point Pharma EPS misses by $0.07

Oyster Point Pharma (OYST): Q4 GAAP EPS of -$0.86 misses by $0.07.As of December 31, 2020, cash and cash equivalents were $192.6M, compared to $139.1M as of December 31, 2019.Press Release For further details see: Oyster Point Pharma EPS misses by $0.07

OYST - Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

OC-01 (Varenicline) Nasal Spray New Drug Application (NDA) Submitted to the U.S. Food and Drug Administration (FDA) for the Treatment of Signs and Symptoms of Dry Eye Disease on December 17, 2020 Phase 2 Clinical Trial Protocol of OC-01 (Varenicline) Nasal Spray in Patients with...

OYST - Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

PRINCETON, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...
OYST - Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

OYST - Oyster Point Pharma files US application for its lead program in dry eye disease

Oyster Point Pharma (OYST) has submitted a marketing application to the FDA seeking approval for its lead candidate, OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease.The submission is supported by safety and efficacy results from the Phase 3 ONSE...

OYST - Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

PRINCETON, N.J., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced it...
OYST - Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers

PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

OYST - Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)

PRINCETON, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced it...

OYST - Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...
Previous 10 Next 10